10 hours Ago By ABMN Staff
Fennec Pharmaceuticals ( NASDAQ:FENC – Get Free Report ) and C4 Therapeutics ( NASDAQ:CCCC – Get Free Report ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership. Profitability This table compares Fennec Pharmaceuticals and C4 Therapeutics’ net margins, return on equity and return on assets. Valuation and Earnings This table compares Fennec Pharmaceuticals and C4 Therapeutics”s revenue, earnings per share (EPS) and valuation.
Risk & Volatility Fennec Pharmaceuticals has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 2.
95, suggesting that its stock price is 195% more volatile than the S&P 500. Institutional and Insider Ownership 55.5% of Fennec Pharmaceuticals shares are held by institutional investors.
Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 11.
0% of Fennec Pharmaceuticals shares are held by company insiders. Comparatively, 8.6% of C4 Therapeutics shares are held by company insiders.
Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Analyst Ratings This is a summary of current ratings for Fennec Pharmaceuticals and C4 Therapeutics, as provided by MarketBeat.com.
Fennec Pharmaceuticals currently has a consensus price target of $13.67, suggesting a potential upside of 105.51%.
C4 Therapeutics has a consensus price target of $11.60, suggesting a potential upside of 285.38%.
Given C4 Therapeutics’ higher possible upside, analysts clearly believe C4 Therapeutics is more favorable than Fennec Pharmaceuticals. Summary Fennec Pharmaceuticals beats C4 Therapeutics on 8 of the 14 factors compared between the two stocks. About Fennec Pharmaceuticals ( Get Free Report ) Fennec Pharmaceuticals Inc.
, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc.
and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc.
was founded in 1996 and is based in Research Triangle Park, North Carolina. About C4 Therapeutics ( Get Free Report ) C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases.
Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F.
Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co.
, Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
